| Chapter title |
Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia
|
|---|---|
| Chapter number | 81 |
| Book title |
Mechanisms of Drug Resistance in Cancer Therapy
|
| Published in |
Handbook of experimental pharmacology, January 2018
|
| DOI | 10.1007/164_2017_81 |
| Pubmed ID | |
| Book ISBNs |
978-3-03-010506-8, 978-3-03-010507-5
|
| Authors |
Federico Lussana, Tamara Intermesoli, Paola Stefanoni, Alessandro Rambaldi, Lussana, Federico, Intermesoli, Tamara, Stefanoni, Paola, Rambaldi, Alessandro |
| Abstract |
Patients with newly diagnosed chronic myeloid leukemia (CML) usually received as first-line treatment a first- or second-generation tyrosine kinase inhibitor (TKI). Although initial responses are high, therapy fails in up to 40% of patients and initial response is lost within 2 years in approximately 25% of patients. In the last few years, intensive efforts have been spent to explain treatment failure, and different mechanisms of resistance have been identified, ranging from BCR-ABL1 kinase domain mutations to lack of adherence to therapy. In this review, we briefly summarize the clinical efficacy of approved TKIs and describe the main mechanisms of TKI resistance. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 34 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 21% |
| Researcher | 4 | 12% |
| Student > Ph. D. Student | 3 | 9% |
| Professor | 3 | 9% |
| Student > Bachelor | 2 | 6% |
| Other | 3 | 9% |
| Unknown | 12 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Computer Science | 1 | 3% |
| Other | 3 | 9% |
| Unknown | 13 | 38% |